Hanne van der Heijden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hanne van der Heijden has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Vanessa Rameh
Department of Radiology, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA
3 shared publicationsItamar Ronen
Clinical Imaging Science Center, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
2 shared publicationsJaymin Upadhyay
Department of Anesthesiology Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publicationsMerve Koç Yekedüz
Department of Anesthesiology Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publicationsRaquel van Gool
Department of Anesthesiology Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publicationsRobert P. Sundel
Division of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- 23 April 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (3) , e70193
Multimodal Noninvasive Biomarker Characterization of Structural and Functional Alterations in ADSS1 ‐Deficient Myopathy
Adenylosuccinate synthase 1 (ADSS1)‐deficient myopathy is an ultra‐rare disease characterized by progressive muscle dysfunction. The objective of this investigation was to employ a noninvasive biomarker approach to phenotype (fine‐)motor skills, communication and cognition in adults with ADSS1‐deficient myopathy. Five individuals with ADSS1‐deficient myopathy and five age‐sex‐matched healthy controls (HCs) underwent a multimodal evaluation. Assessments included, (i) evaluation of motor performance, (ii) speech and voice production and cognitive test batteries, (iii) patient‐reported outcomes, (iv) electrical impedance myography (EIM), (v) musculoskeletal magnetic resonance imaging (MRI), and (vi) plasma proteomics. ADSS1‐deficient myopathy participants vs. HCs demonstrated reduced performance on the 9‐Hole Peg and grip strength tests as well as lower self‐reported mobility. Analysis of speech and voice performance revealed asthenia (vocal weakness) ( p = 0.02), lower intelligibility ( p = 0.008), and worse voice quality during the sustained vowel task ( p = 0.03) in the ADSS1‐deficient myopathy cohort. Cognitive functioning remained unaffected in patients with ADSS1‐deficient myopathy. On EIM, ADSS1‐deficient myopathy participants vs. HCs, demonstrated a pattern of higher resistance and lower reactance and phase across upper‐ and lower‐extremity measurements, indicative of poorer muscle health, with large effect sizes (Cliff's δ = 0.5–0.9). MRI revealed intramuscular fat infiltration, particularly in posterior compartments of the upper leg (e.g., biceps femoris). Proteomics indicated reduced ( p = 0.04) Neurotrophin‐3 (NTF3; implicated in neuronal development, survival, and differentiation) levels in the ADSS1‐deficient myopathy cohort relative to HCs. Lower NTF3 levels associated with poorer performance on hand‐motor tasks as well as higher resistance and lower reactance and phase on EIM. This study highlighted the value of multimodal phenotyping for quantifying disease expression and advancing monitoring strategies in ADSS1‐deficient myopathy. This multimodal investigation demonstrates that integrating electrical impedance myography with quantitative motor, speech, musculoskeletal imaging, and proteomic assessments provides a sensitive and noninvasive research framework for capturing neuromuscular dysfunction and functional disease burden in patients with ADSS1‐deficient myopathy, thereby supporting the current biomarker strategy for refined phenotyping and longitudinal disease monitoring in this ultra‐rare condition.
- 23 April 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (3) , e70193
Multimodal Noninvasive Biomarker Characterization of Structural and Functional Alterations in ADSS1 ‐Deficient Myopathy
Adenylosuccinate synthase 1 (ADSS1)‐deficient myopathy is an ultra‐rare disease characterized by progressive muscle dysfunction. The objective of this investigation was to employ a noninvasive biomarker approach to phenotype (fine‐)motor skills, communication and cognition in adults with ADSS1‐deficient myopathy. Five individuals with ADSS1‐deficient myopathy and five age‐sex‐matched healthy controls (HCs) underwent a multimodal evaluation. Assessments included, (i) evaluation of motor performance, (ii) speech and voice production and cognitive test batteries, (iii) patient‐reported outcomes, (iv) electrical impedance myography (EIM), (v) musculoskeletal magnetic resonance imaging (MRI), and (vi) plasma proteomics. ADSS1‐deficient myopathy participants vs. HCs demonstrated reduced performance on the 9‐Hole Peg and grip strength tests as well as lower self‐reported mobility. Analysis of speech and voice performance revealed asthenia (vocal weakness) ( p = 0.02), lower intelligibility ( p = 0.008), and worse voice quality during the sustained vowel task ( p = 0.03) in the ADSS1‐deficient myopathy cohort. Cognitive functioning remained unaffected in patients with ADSS1‐deficient myopathy. On EIM, ADSS1‐deficient myopathy participants vs. HCs, demonstrated a pattern of higher resistance and lower reactance and phase across upper‐ and lower‐extremity measurements, indicative of poorer muscle health, with large effect sizes (Cliff's δ = 0.5–0.9). MRI revealed intramuscular fat infiltration, particularly in posterior compartments of the upper leg (e.g., biceps femoris). Proteomics indicated reduced ( p = 0.04) Neurotrophin‐3 (NTF3; implicated in neuronal development, survival, and differentiation) levels in the ADSS1‐deficient myopathy cohort relative to HCs. Lower NTF3 levels associated with poorer performance on hand‐motor tasks as well as higher resistance and lower reactance and phase on EIM. This study highlighted the value of multimodal phenotyping for quantifying disease expression and advancing monitoring strategies in ADSS1‐deficient myopathy. This multimodal investigation demonstrates that integrating electrical impedance myography with quantitative motor, speech, musculoskeletal imaging, and proteomic assessments provides a sensitive and noninvasive research framework for capturing neuromuscular dysfunction and functional disease burden in patients with ADSS1‐deficient myopathy, thereby supporting the current biomarker strategy for refined phenotyping and longitudinal disease monitoring in this ultra‐rare condition.
- Open Access
- 11 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152916
Fronto-cerebellar features associate with cognitive dysfunction in childhood-onset systemic lupus erythematosus
- 11 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152916
Open AccessFronto-cerebellar features associate with cognitive dysfunction in childhood-onset systemic lupus erythematosus
- 19 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (3) , 332-344
Implications of Inflammatory Processes on a Developing Central Nervous System in Childhood‐Onset Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is increasingly affecting pediatric and adult populations. Neuropsychiatric manifestations (ie, cognitive dysfunction and mood disorders) appear to occur with greater severity and poorer prognosis in childhood‐onset SLE (cSLE) versus adult‐onset SLE, negatively impacting school function, self‐management, and psychosocial health, as well as lifelong health‐related quality of life. In this review, we describe pathogenic mechanisms active in cSLE, such as maladaptive inflammatory processes and ischemia, which are hypothesized to underpin central phenotypes in patients with cSLE, and the role of alterations in protective central nervous system (CNS) barriers (ie, the blood–brain barrier) are also discussed. Recent findings derived from novel neuroimaging approaches are highlighted because the methods employed in these studies hold potential for identifying CNS abnormalities that would otherwise remain undetected with conventional multiple resonance imaging studies (eg, T2‐weighted or fluid‐attenuated inversion recovery sequences). Furthermore, we propose that a more robust presentation of neuropsychiatric symptoms in cSLE is in part due to the harmful impact of a chronic inflammatory insult on a developing CNS. Although the immature status of the CNS may leave patients with cSLE more vulnerable to harboring neuropsychiatric manifestations, the same property may represent a greater urgency to reverse the maladaptive effects associated with a proneuroinflammatory state, provided that effective diagnostic tools and treatment strategies are available. Finally, considering the crosstalk among the CNS and other organ systems affected in cSLE, we postulate that a finer understanding of this interconnectivity and its role in the clinical presentation in cSLE is warranted. image
- 19 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (3) , 332-344
Implications of Inflammatory Processes on a Developing Central Nervous System in Childhood‐Onset Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is increasingly affecting pediatric and adult populations. Neuropsychiatric manifestations (ie, cognitive dysfunction and mood disorders) appear to occur with greater severity and poorer prognosis in childhood‐onset SLE (cSLE) versus adult‐onset SLE, negatively impacting school function, self‐management, and psychosocial health, as well as lifelong health‐related quality of life. In this review, we describe pathogenic mechanisms active in cSLE, such as maladaptive inflammatory processes and ischemia, which are hypothesized to underpin central phenotypes in patients with cSLE, and the role of alterations in protective central nervous system (CNS) barriers (ie, the blood–brain barrier) are also discussed. Recent findings derived from novel neuroimaging approaches are highlighted because the methods employed in these studies hold potential for identifying CNS abnormalities that would otherwise remain undetected with conventional multiple resonance imaging studies (eg, T2‐weighted or fluid‐attenuated inversion recovery sequences). Furthermore, we propose that a more robust presentation of neuropsychiatric symptoms in cSLE is in part due to the harmful impact of a chronic inflammatory insult on a developing CNS. Although the immature status of the CNS may leave patients with cSLE more vulnerable to harboring neuropsychiatric manifestations, the same property may represent a greater urgency to reverse the maladaptive effects associated with a proneuroinflammatory state, provided that effective diagnostic tools and treatment strategies are available. Finally, considering the crosstalk among the CNS and other organ systems affected in cSLE, we postulate that a finer understanding of this interconnectivity and its role in the clinical presentation in cSLE is warranted. image